The impact of TLR signaling on osteoclast-mediated bone remodeling and inflammation in osteoarthritis.

NIH RePORTER · NIH · F31 · $48,974 · view on reporter.nih.gov ↗

Abstract

Project Summary/ Abstract Osteoarthritis (OA), one of the leading causes of disability in the US, is characterized by cartilage degradation, synovitis, and subchondral bone remodeling. While there are currently no treatments for OA, there is increasing evidence that chronic low-level inflammation plays a role in driving disease progression. Inflammation during OA manifests as the infiltration of joint tissues (especially the synovium and subchondral bone) by immune cells, including macrophages, T cells, and NK cells. Although mechanisms driving synovial inflammation are currently an intense area of study, little is known regarding how inflammation in the subchondral bone (SCB) occurs and its consequences on remodeling and joint homeostasis. Recently, Toll-like receptor (TLR)-mediated inflammatory pathways have been implicated in OAassociated synovitis, cartilage erosion, and bone remodelling. Our previous work demonstrated that mice deficient in CD14, a TLR co-receptor, are partially protected from disease in a post-traumatic OA model. Specifically, CD14- deficiency resulted in a significant reduction in SCB bone thickening and cartilage damage after joint-injury compared to wild type mice, with the most substantial amelioration of the SCB pathology. OA bone pathology extends beyond signs of remodeling, and also includes an increase in inflammatory cells in the bone marrow. 1bis inflammation may contribute to pain in OA, but the mechanisms driving SCB inflammation are poorly studied. Thus, I propose that TLR signalling in osteoclasts modulates the osteoclast secretome, resulting in osteoblastogenesis as well as T cell migration. To explore this, I will first show in vitro that TLR signaling leads to the release of factors that are both proinflammatory and osteoblastogenic (Aim 1 ). Next, I will use IMC to characterize the T cell landscape in the subchondral bone of osteoarthritic mice and determine anatomic associations between T cells and osteoclasts 1 (Aim 2a). Lastly, I plan to develop a novel osteoclast T cell migration assay to show that TLR signaling in osteoclasts increases proinflammatory T cell migration (Aim 2b). Successful completion of these Aims will provide a better understanding of the cellular and tissue-level changes that occur in the subchondral bone in OA, as well as new targets for therapeutic intervention. I have collected a significant amount of preliminary data, motivating the direction of these aims and showcasing the skillset and tools I have already become proficient in. Additionally, with the help of my mentors as well as my collaborators Dr. Su and Dr. Liu, I have all the necessary expertise to ensure the successful completion of this project.

Key facts

NIH application ID
10996052
Project number
1F31AR084868-01
Recipient
UNIVERSITY OF PENNSYLVANIA
Principal Investigator
Lance Avery Murphy
Activity code
F31
Funding institute
NIH
Fiscal year
2024
Award amount
$48,974
Award type
1
Project period
2024-08-01 → 2027-07-31